Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

Pigment Cell and Melanoma Research

Volumn 21, Issue 4, 2008, Pages 492-493

  Lutzky, Jose ^a   Bauer, Juergen ^b   Bastian, Boris C ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Imatinib; KIT; Melanoma; Targeted therapy

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IMATINIB; STEM CELL FACTOR;

AGED; ANUS CANCER; ASPIRATION BIOPSY; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE NUMBER; HEMORRHOID; HEMORRHOIDECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SUBCUTANEOUS NODULE; SUN EXPOSURE; TREATMENT RESPONSE;

AGED; AMINO ACID SUBSTITUTION; ANUS NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUTAMIC ACID; HUMANS; INTESTINAL MUCOSA; LYSINE; MELANOMA; NEOPLASM METASTASIS; PIPERAZINES; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; REMISSION INDUCTION;

EID: 47249099056     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2008.00475.x     Document Type: Letter

References (9)

1. Alexis, J.B., Martinez, A.E. Lutzky, J. (2005). An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res. 15, 283 285.
2. Curtin, J.A., Busam, K., Pinkel, D. Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 1 9.
3. Eton, O., Billings, L., Kim, K. et al. (2004). Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma. J. Clin. Oncol. 22, 7528a.
4. Fiorentini, G., Rossi, S., Lanzanova, G. et al. (2003). Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing C-KIT(CD117): preliminary results of a compassionate use clinical trial. J. Exp. Clin. Cancer Res. 22 (Suppl. 17 20.
5. Heinrich, M.C., Corless, C.L., Demetri, G.D. et al. (2006). Kinase mutations in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342 4349.
6. Podnos, Y.D., Tsai, N.C., Smith, D. Ellenhorn, J.D. (2006). Factors affecting survival in patients with anal melanoma. Am. Surg. 72, 917 920.
7. Tsao, M.S., Sakurada, A., Cutz, J.C. et al. (2005). Erlotinib in lung cancer-molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133 144.
8. Ugurel, S., Hildenbrand, R., Zimpfer, A. et al. (2005). Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer 92, 1398 1405.
9. Wyman, K., Atkins, M.B., Prieto, V. et al. (2006). Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106, 2005 2011.